Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 18239009.
- Also identified by DOI 10.1097/01.AOG.0000281670.94265.5c.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Uterocutaneous fistula is a rare complication of uterine surgery. All published cases have been surgically treated with hysterectomy and excision of the fistulous tract. We report a case of uterocutaneous fistula that was successfully treated with gonadotropin-releasing hormone agonist administration. A 25-year-old woman reported bloody discharge during her periods from a previous Pfannenstiel incision. A fistulous tract leading from the incision scar to the uterus was diagnosed. Leuprolide acetate depot was administered twice subcutaneously at a dose of 11.25 mg. The fistulous tract closed spontaneously, and the patient was symptom free thereafter. Medical treatment with gonadotropin-releasing hormone agonists should be considered before resorting to surgery for treatment of uterocutaneous fistulae.
Medical subject headings
- Antineoplastic Agents, Hormonal
- Cutaneous Fistula
- Gonadotropin-Releasing Hormone
- Leuprolide
- Uterine Diseases